Aqua Pharmaceuticals is a specialty dermatology company focusing on acquiring, developing and marketing prescription medical dermatology products in the United States. Currently marketed products include: ACTICLATE® (doxycycline hyclate USP) Tablets, CORDRAN® (flurandrenolide USP) Lotion, Cream, and Ointment, 0.05%, FLUOROPLEX® (fluorouracil) 1% Topical Cream, XOLEGEL® (ketaconazole) Gel, 2%, VERDESO® (desonide) Foam, 0.05%, and MONODOX® (doxycycline monohydrate) Capsules. An essential element in Aqua's strategy for strong, sustainable growth is to build beyond the current product portfolio by developing, licensing, and acquiring products for the treatment of skin conditions. Importantly, Aqua looks to expand its opportunities through product development, in-licensing, co-promotion, product or company acquisition, and partnerships. In December 2013, Almirall S.A. entered into a definitive agreement to acquire Aqua Pharmaceuticals. Almirall is a pharmaceutical company committed to provide valuable medicines through its own R&D efforts together with external partnerships, licenses, and collaborations. Through seeking innovative medicines, Almirall aims to be a relevant player in dermatology, in addition to having a strong interest in gastroenterology and pain. With more than 3,000 employees in 23 countries, Almirall generated total revenues of €825 million in 2013. The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded on the Spanish stock exchange (ticker: ALM).